A citation-based method for searching scientific literature

David Waterhouse, Jenny Lam, Keith A Betts, Lei Yin, Sophie Gao, Yong Yuan, John Hartman, Sumati Rao, Solomon Lubinga, David Stenehjem. Lung Cancer 2021
Times Cited: 3







List of co-cited articles
2 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands.
Christine M Cramer-van der Welle, Marjon V Verschueren, Merel Tonn, Bas J M Peters, Franz M N H Schramel, Olaf H Klungel, Harry J M Groen, Ewoudt M W van de Garde. Sci Rep 2021
3
66

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
66

Opportunities and challenges in leveraging electronic health record data in oncology.
Marc L Berger, Melissa D Curtis, Gregory Smith, James Harnett, Amy P Abernethy. Future Oncol 2016
57
33

The use of nonrandomized evidence to estimate treatment effects in health technology assessment.
Seamus Kent, Maximilian Salcher-Konrad, Stefania Boccia, Jacoline C Bouvy, Chiara de Waure, Jaime Espin, Karen Facey, Mary Nguyen, Juan Carlos Rejon-Parrilla, Pall Jonsson. J Comp Eff Res 2021
2
50

Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
Kenneth L Kehl, Scott Greenwald, Nassib G Chamoun, Paul J Manberg, Deborah Schrag. JAMA Netw Open 2021
2
50

Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer.
Xinke Zhang, Richard W DeClue, Lisa Herms, Mo Yang, Vivek Pawar, Elizabeth T Masters, Mary Ruisi, Kevin Chin, Vamsidhar Velcheti. Immunotherapy 2021
1
100



Synthetic and External Controls in Clinical Trials - A Primer for Researchers.
Kristian Thorlund, Louis Dron, Jay J H Park, Edward J Mills. Clin Epidemiol 2020
22
33

Per-Protocol Analyses of Pragmatic Trials.
Miguel A Hernán, James M Robins. N Engl J Med 2017
167
33

First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
Karim Amrane, Margaux Geier, Romain Corre, Hervé Léna, Guillaume Léveiller, Florence Gadby, Régine Lamy, Jean-Louis Bizec, Eric Goarant, Gilles Robinet,[...]. Cancer Med 2020
16
33

Real-world evidence and nonrandomized data in health technology assessment: using existing methods to address unmeasured confounding?
Cormac J Sammon, Thomas P Leahy, Sandro Gsteiger, Sreeram Ramagopalan. J Comp Eff Res 2020
4
33

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
Vanesa Gregorc, Silvia Novello, Chiara Lazzari, Sandro Barni, Michele Aieta, Manlio Mencoboni, Francesco Grossi, Tommaso De Pas, Filippo de Marinis, Alessandra Bearz,[...]. Lancet Oncol 2014
125
33

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Luis Paz-Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Barbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp,[...]. N Engl J Med 2018
33

Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
Vincenzo Di Noia, Ettore D'Argento, Sara Pilotto, Emanuele Vita, Miriam Grazia Ferrara, Paola Damiano, Marta Ribelli, Antonella Cannella, Antonella Virtuoso, Andrea Fattorossi,[...]. Cancer Immunol Immunother 2021
3
33

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
33

Dynamic Immune/Inflammation Precision Medicine: The Good and the Bad Inflammation in Infection and Cancer.
Jean-François Rossi, Zhao Yang Lu, Cesare Massart, Kalle Levon. Front Immunol 2021
13
33


SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors.
Enrico Milan, Chiara Lazzari, Santosh Anand, Irene Floriani, Valter Torri, Cristina Sorlini, Vanesa Gregorc, Angela Bachi. J Proteomics 2012
48
33

Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors.
Chiara Lazzari, Anna Spreafico, Angela Bachi, Heinrich Roder, Irene Floriani, Daniela Garavaglia, Angela Cattaneo, Julia Grigorieva, Maria Grazia Viganò, Cristina Sorlini,[...]. J Thorac Oncol 2012
31
33

Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies.
Cássia Rita Pereira da Veiga, Claudimar Pereira da Veiga, Ana Paula Drummond-Lage. Crit Rev Oncol Hematol 2018
12
33

The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
Mary Jo Fidler, Cristina L Fhied, Joanna Roder, Sanjib Basu, Selina Sayidine, Ibtihaj Fughhi, Mark Pool, Marta Batus, Philip Bonomi, Jeffrey A Borgia. BMC Cancer 2018
21
33

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Elizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, Anastasiya Lobachov, Rinat Mandelboim, Tzippy Shochat, Damien Urban, Mira Wollner, Hovav Nechushtan, Ofer Rotem,[...]. Oncoimmunology 2021
3
33

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.
D Ross Camidge, Robert C Doebele, Keith M Kerr. Nat Rev Clin Oncol 2019
151
33


Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
Fumiko Taguchi, Benjamin Solomon, Vanesa Gregorc, Heinrich Roder, Robert Gray, Kazuo Kasahara, Makoto Nishio, Julie Brahmer, Anna Spreafico, Vienna Ludovini,[...]. J Natl Cancer Inst 2007
214
33

Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis.
Ticiana A Leal, Angela C Argento, Krish Bhadra, D Kyle Hogarth, Julia Grigorieva, Rachel M Hartfield, Robert C McDonald, Philip D Bonomi. Curr Med Res Opin 2020
2
50

Mass Spectrometry-Based Multivariate Proteomic Tests for Prediction of Outcomes on Immune Checkpoint Blockade Therapy: The Modern Analytical Approach.
Julia Grigorieva, Senait Asmellash, Lelia Net, Maxim Tsypin, Heinrich Roder, Joanna Roder. Int J Mol Sci 2020
4
33

Inflammatory Markers in Cancer Immunotherapy.
Deepak Ravindranathan, Viraj A Master, Mehmet Asim Bilen. Biology (Basel) 2021
3
33

Hallmarks of response to immune checkpoint blockade.
Alexandria P Cogdill, Miles C Andrews, Jennifer A Wargo. Br J Cancer 2017
117
33

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
Gaurav Singal, Peter G Miller, Vineeta Agarwala, Gerald Li, Gaurav Kaushik, Daniel Backenroth, Anala Gossai, Garrett M Frampton, Aracelis Z Torres, Erik M Lehnert,[...]. JAMA 2019
151
33

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
33

Explaining multivariate molecular diagnostic tests via Shapley values.
Joanna Roder, Laura Maguire, Robert Georgantas, Heinrich Roder. BMC Med Inform Decis Mak 2021
1
100



Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.
David P Carbone, Keyue Ding, Heinrich Roder, Julia Grigorieva, Joanna Roder, Ming-Sound Tsao, Lesley Seymour, Frances A Shepherd. J Thorac Oncol 2012
85
33

First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Ryul Kim, Bhumsuk Keam, Seokyung Hahn, Chan-Young Ock, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo. Clin Lung Cancer 2019
24
33

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
David P Carbone, Martin Reck, Luis Paz-Ares, Benjamin Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M van den Heuvel, Tudor-Eliade Ciuleanu, Firas Badin,[...]. N Engl J Med 2017
33

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
Edward B Garon, Matthew D Hellmann, Naiyer A Rizvi, Enric Carcereny, Natasha B Leighl, Myung-Ju Ahn, Joseph Paul Eder, Ani S Balmanoukian, Charu Aggarwal, Leora Horn,[...]. J Clin Oncol 2019
343
33

Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non-Small Cell Lung Carcinoma.
Hestia Mellert, Trudi Foreman, Leisa Jackson, Dianna Maar, Scott Thurston, Kristina Koch, Amanda Weaver, Samantha Cooper, Nicholas Dupuis, Ubaradka G Sathyanarayana,[...]. J Mol Diagn 2017
18
33

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Nasser H Hanna, Bryan J Schneider, Sarah Temin, Sherman Baker, Julie Brahmer, Peter M Ellis, Laurie E Gaspar, Rami Y Haddad, Paul J Hesketh, Dharamvir Jain,[...]. J Clin Oncol 2020
102
33

Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors.
Ernest Nadal, Bartomeu Massuti, Manuel Dómine, Rosario García-Campelo, Manuel Cobo, Enriqueta Felip. Cancer Immunol Immunother 2019
47
33


Cancer statistics, 2018.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2018
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.